期刊文献+

HPLC法测定甲氧氯普胺中有关物质的含量 被引量:1

Determination of the Contents of the Related Substances in Metoclopramide by HPLC
原文传递
导出
摘要 目的:建立以高效液相色谱法测定甲氧氯普胺中有关物质含量的方法。方法:色谱柱为C18,流动相为乙腈-0.02mol.L-1磷酸溶液(19∶81),流速为1.0mL.min-1,检测波长为275nm,柱温为室温,进样量为20μL;以主成分自身对照法计算有关物质的含量。结果:在该色谱条件下,甲氧氯普胺与杂质能完全分离;杂质限量在0.05%~4.0%范围内测得的峰面积与样品自身对照溶液的浓度呈良好的线性关系;甲氧氯普胺的最小检出量为0.3ng,其有关物质的含量均小于0.26%。结论:本方法简便、准确、灵敏度高、专属性强,可用于甲氧氯普胺中有关物质的检测。 OBJECTIVE: To establish an HPLC method for the determination of the contents of the related substances in metoclopramide. METHODS: The sample was separated on C18 column with the mobile phase consisted of acetonitrile - 0.02 mol·L^-1 phosphonic acid solution (19 : 81) at a flow rate of 1.0 mL·min^-1. The detection wavelength was set at 275 nm; the column temperature was kept under room temperature and the injected volume was 20μL. The contents of the related substances in metoclopramide were computed by self - control method of main constituent. RESULTS: Under the above described chromatographic conditions, metoclopramide was completely separated from its impurities. A good linearity between impurities' peak area and metoclopramide (contrast solution) concentration was achieved when the concentrations of impurities were over the range of 0.05%~4.0%. The lowest detectable limit of metoclopramide was 0.3 ng, and the contents of the related substances were all less than 0.26%. CONCLUSION: The method is convenient, accurate, sensitive and, specific, and it can be used for the determination of the related substances in metoclopramide.
出处 《中国药房》 CAS CSCD 北大核心 2009年第13期1008-1010,共3页 China Pharmacy
基金 河北省科技攻关课题(07276426)
关键词 高效液相色谱法 甲氧氯普胺 有关物质 HPLC Metoclopramide Related substances
作者简介 田兰,副主任药师。研究方向:药物分析。电话:0311-852120048038。E-mail:tianlan921@sina.com
  • 相关文献

参考文献4

二级参考文献10

  • 1[1]Ormrod D,Goa KL.Intranasal metoclopramide [J].Drugs,1999,58(2):315-322.
  • 2[2]Scaglione F,Scanni A,Tomirotti M,et al.Pharmacokinetics and bioavailability of metoclopramide nasal spray versus metoclopramide intravenous in healthy volunteers and cancer patients [J].J Clin Pharmacol,1997,37(10):979-985.
  • 3[3]Ward MJ,Buss DC,Ellershaw J,et al.Bioavailability of Intranasal metoclopramide [J].Br J Clin Pharmac,1989,28:616-618.
  • 4张家铨 吴景时 程鹏.常用药物手册(第二版)[M].北京:人民卫生出版社,2000.536.
  • 5Lars S, Per SP, Ulf A, et al. A simple HPLC method for measuring metoclopramide in serum. Acta Pharmacol Toxicol, 1986,58:240.
  • 6Jong AD, Wittebrood A J, Chatinier WM ,et al. Liquid chromatographic analysis of alizapfide and metoclopramide in human plasma and urine using solidphase extraction. J Chromatogr Biomed Appl, 1987,419:233.
  • 7Magueur E,Hagege H,Attali P, et al. Pharmacokinetics of metoclopramide in patients with liver cirrhosis. Br J Clin Pharmacol, 1991,31:185.
  • 8张晓霞,韩培红.马来酸桂哌齐特的药理作用及临床应用研究[J].中国药房,2007,18(26):2060-2062. 被引量:149
  • 9凌大奎.有关物质及其高效液相色谱测定法[J].中国药学杂志,2000,35(8):567-569. 被引量:42
  • 10邹梅娟,程刚,崔福德,刘国良,郝秀华,李蔚雯.结肠定位释药双氯芬酸钠包衣片体内外相关性[J].沈阳药科大学学报,2002,19(6):391-394. 被引量:4

共引文献19

同被引文献13

  • 1梁成罡,李克坚,张慧,杨化新,徐康森.重组人甲状旁腺激素的质量研究[J].药物分析杂志,2005,25(2):215-219. 被引量:7
  • 2李晓东.骨质疏松症治疗药 特立帕肽(teriparatide)[J].世界临床药物,2005,26(9):572-573. 被引量:4
  • 3廖海明,曾文珊,杨仲元,徐康森.HPLC法测定重组人甲状旁腺素1-34肽含量及有关物质[J].药物分析杂志,2006,26(1):27-29. 被引量:2
  • 4李发美.分析化学[M].北京:人民卫生出版社.2007:398.
  • 5Anastasilakis AD, Goulis DG, Polyzos SA, et al. Head- to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteopo- rosis- a randomized trial[J]. Int J Clin Pract, 2008, 62 (6):919.
  • 6Keaveny TM, Donley DW, Hoffmann PF, et al. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in wom-en with osteoporosis[J]. JBone Miner Res, 2007, 22( 1 ) : 149.
  • 7Clung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in in- creasing bone mass[J]. Arch Intern Med, 2005, 165 (15) : 1 762.
  • 8Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis treatment and discontinuation of therapy[J]. Osteoporos Int, 2005,16(5) : 510.
  • 9Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronatein glucocorticoid-induced osteoporosis[J]. N Engl JMed, 2007,357(20) : 2 028.
  • 10Kamp RM,Choli-Papadopoulou T 著.施蕴渝,饶子和译.蛋白质结构分析:制备、鉴定和微量测序[M].北京:科学出版社,2002:50.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部